4D Molecular Therapeutics (FDMT) News Today

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 7% Higher

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase

Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of 4D Molecular Therapeutics in a report on Monday.

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 6.8% After Analyst Downgrade

BMO Capital Markets dropped their target price on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an "outperform" rating on the stock in a research report on Thursday.

Chardan Capital reaffirmed a "buy" rating and issued a $38.00 price objective on shares of 4D Molecular Therapeutics in a report on Wednesday.

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.75

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) CEO David Kirn sold 12,923 shares of the company's stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total transaction of $290,638.27. Following the transaction, the chief executive officer now directly owns 1,059,153 shares of the company's stock, valued at $23,820,350.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 6.9%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.36, for a total transaction of $90,737.28. Following the completion of the transaction, the insider now directly owns 1,737 shares in the company, valued at $37,102.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Goldman Sachs Group Inc. raised its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 415.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 816,343 shares of the

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) CEO David Kirn sold 12,930 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $23.10, for a total transaction of $298,683.00. Following the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 4.5%

Royal Bank of Canada reissued an "outperform" rating and set a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Wednesday.

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 5.2%

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned an average recommendation of "Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy rating. The average 12-month price targe

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 3.6%

Rafferty Asset Management LLC cut its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,589 shares of the company's

Sectoral Asset Management Inc. acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 142,510 shares

HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday.

Franklin Resources Inc. raised its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 266.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,564 shares of the co

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 7.5%

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down on Insider Selling

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $25.45, for a total transaction of $44,537.50. Following the transaction, the insider now directly owns 1,737 shares of the company's stock, valued at approximately $44,206.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 3.6%

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.07. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, May 13th. HC Wainwright analyst M. Caufield now expects t